Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 7/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.38 |
| ▸ | PIM1 | P11309 | 3/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192676 | 0.89 | CCNT1 (0.55) | CCNT1PIM2PIM1KDR | |
| SCHEMBL3366294 | 0.83 | HRH1 (0.45) | CCNT1CDK2HRH1DRD2HTR2A | |
| SCHEMBL12501667 | 0.81 | CCNT1 (0.44) | CCNT1KDR | |
| SCHEMBL28884717 | 0.79 | PDE10A (0.39) | CCNT1PIM2PIM1PTGER4PIM3 | |
| SCHEMBL29933884 | 0.79 | PDE10A (0.39) | CCNT1PIM2PIM1PTGER4PIM3 | |
| SCHEMBL23501704 | 0.77 | PDE10A (0.38) | CCNT1PIM2PIM1PTGER4PIM3 | |
| SCHEMBL6658816 | 0.77 | IRAK4 (0.43) | CCNT1 | |
| SCHEMBL6659258 | 0.77 | HRH1 (0.50) | CDK2HRH1DRD2HTR2AKDR | |
| SCHEMBL16333975 | 0.75 | IDH1 (0.43) | CCNT1PIM2PIM1 | |
| SCHEMBL6221844 | 0.72 | P2RX7 (0.43) | CCNT1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115139-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-25 | — | — | US | disclosed |
| EP-2442870-B1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8324201-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8318722-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8314088-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20120135979-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-31 | — | — | US | disclosed |
| CN-102458579-A | Pyrazinoazeza derivatives | TAKEDA PHARMACEUTICAL | 2012-05-16 | — | — | CN | disclosed |
| EP-2442870-A1 | PYRAZINOOXAZEPINE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20110288291-A1 | PYRAZINOOXAZEPINE DERIVATIVES | SASAKI SHIGEKAZU (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110282054-A1 | PYRAZINOOXAZEPINE DERIVATIVES | SASAKI SHIGEKAZU (JP) | 2011-11-17 | — | — | US | disclosed |
| WO-2010147226-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | WO | disclosed |
| US-20100317651-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135979-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR5A, HTR2C, HTR2A | CCNT1 3605/4885CDK2 1871/4885HRH1 1388/4885 |
| US-20100317651-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | CCNT1 3309/4885CDK2 1006/4885HRH1 463/4885 |
| US-20110288291-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | CCNT1 3309/4885CDK2 1006/4885HRH1 463/4885 |
| US-20110282054-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | CCNT1 3309/4885CDK2 1006/4885HRH1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.